113 related articles for article (PubMed ID: 6547268)
1. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of piperazinedione (NCS 135758) in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
Thigpen JT; Blessing J; Homesley HD; Adcock LL
Am J Clin Oncol; 1983 Aug; 6(4):423-6. PubMed ID: 6688150
[TBL] [Abstract][Full Text] [Related]
3. Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group.
Thigpen JT; Lagasse L; Homesley H; Blessing JA
Am J Clin Oncol; 1983 Aug; 6(4):431-5. PubMed ID: 6683465
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Homesley HD; Hacker N; Curry SL
Am J Clin Oncol; 1985 Oct; 8(5):350-2. PubMed ID: 3840643
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study.
Thigpen JT; Ehrlich CE; Creasman WT; Curry S; Blessing JA
Am J Clin Oncol; 1983 Jun; 6(3):273-5. PubMed ID: 6846245
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
Conroy JF; Blessing JA; Kessinger A; Homesley HD
Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
[No Abstract] [Full Text] [Related]
7. Piperazinedione in metastatic renal carcinoma.
Pasmantier MW; Coleman M; Kennedy BJ; Eagan R; Carolla R; Weiss R; Leone L; Silver RT
Cancer Treat Rep; 1977 Dec; 61(9):1731-2. PubMed ID: 340039
[No Abstract] [Full Text] [Related]
8. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Lagasse LD; DiSaia PJ; Homesley HD
Am J Clin Oncol; 1984 Jun; 7(3):253-6. PubMed ID: 6539565
[TBL] [Abstract][Full Text] [Related]
9. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
[TBL] [Abstract][Full Text] [Related]
10. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Lewis GC
Gynecol Oncol; 1986 Mar; 23(3):358-63. PubMed ID: 3754234
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Petty W
Am J Clin Oncol; 1986 Feb; 9(1):21-3. PubMed ID: 3754086
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of piperazinedione in metastatic sarcoma.
Presant CA; Bartolucci AA
Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
[TBL] [Abstract][Full Text] [Related]
13. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Thigpen T; Shingleton H; Homesley H; Lagasse L; Blessing J
Cancer; 1981 Aug; 48(4):899-903. PubMed ID: 7196794
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of piperazinedione in patients with advanced cancer.
Currie V; Woodcock T; Tan C; Krakoff I; Young C
Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
Palmer RL; Samal BA; Vaughn CB; Tranum BL
Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
[No Abstract] [Full Text] [Related]
17. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley H; Creasman WT; Sutton G
Gynecol Oncol; 1989 Apr; 33(1):68-70. PubMed ID: 2703169
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of gallium nitrate (NSC #15200) in previously treated ovarian carcinoma. A Gynecologic Oncology Group Study.
Malfetano JH; Blessing JA; Adelson MD
Am J Clin Oncol; 1991 Aug; 14(4):349-51. PubMed ID: 1862766
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Adelson MD; Hanjani P
Invest New Drugs; 1990 Nov; 8(4):377-9. PubMed ID: 2084071
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
McGuire WP; Blessing JA; Berman ML
Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
